Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Mary Garfield, MS 203.906.5693
Consortium02-ctinquiries@vedantabio.com


Azadeh Haghighi, MS Consortium02-ctinquiries@vedantabio.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - VE202 in Patients with Mild-to-Moderate Ulcerative Colitis
Back

VE202 in Patients with Mild-to-Moderate Ulcerative Colitis

Recruiting

Open to: ALL

Age: 18.0 - 75.0

London London London Birmingham

Medical Conditions

Colitis
Colitis, Ulcerative
Ulcer

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

May 2023 Jul 2025

INTERVENTIONAL

Intervention Type : BIOLOGICAL
Intervention Description : VE202 is a rationally defined, live biotherapeutic product for oral administration.

Intervention Arm Group : Group A: Part 1 Active and Part 2 Placebo Treatment with Vancomycin pretreatment.;Group B: Part 1 Placebo and Part 2 Active Treatment with Vancomycin pretreatment.;

Intervention Type : DRUG
Intervention Description : Vancomycin is an antibiotic used to treat or prevent infection

Intervention Arm Group : Group A: Part 1 Active and Part 2 Placebo Treatment with Vancomycin pretreatment.;Group B: Part 1 Placebo and Part 2 Active Treatment with Vancomycin pretreatment.;

Intervention Type : OTHER
Intervention Description : VE202 Placebo

Intervention Arm Group : Group A: Part 1 Active and Part 2 Placebo Treatment with Vancomycin pretreatment.;Group B: Part 1 Placebo and Part 2 Active Treatment with Vancomycin pretreatment.;

Intervention Type : OTHER
Intervention Description : Vancomycin Placebo

Intervention Arm Group : Group A: Part 1 Active and Part 2 Placebo Treatment with Vancomycin pretreatment.;Group B: Part 1 Placebo and Part 2 Active Treatment with Vancomycin pretreatment.;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • King's College Hospital
    London
    SE5 9RS
  • Imperial College Healthcare NHS Trust - St Mary's Hospital
    London
    W2 1NY
  • Barts Health NHS TrustThe Royal London Hospital
    London
    E1 2AJ
  • UHB NHSFT Queen Elizabeth Hospital
    Birmingham
    West Midlands
    B15 2TH

Mary Garfield, MS 203.906.5693
Consortium02-ctinquiries@vedantabio.com


Azadeh Haghighi, MS Consortium02-ctinquiries@vedantabio.com



The study is sponsored by Vedanta Biosciences, Inc.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05370885
Last updated 17 December 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top